CD274 and neoplasm: Interestingly, the two anti–PD-L1 therapies had the strongest effect, with three out of five atezolizumab-treated mice and five out of five avelumab-treated mice rejecting tumor formation out to day 19 after tumor injection (Fig. 4F).